First-of-its-kind Guillain-Barré drug that switches off part of the immune system could be approved next year

New Scientist posted on X on Aug. 4 that a first-of-its-kind Guillain-Barre drug that switches off part of the immune system could be approved for use next year. The post links to a New Scientist article about the first targeted treatment for Guillain-Barre syndrome nearing approval. The drug works by switching off part of the immune system. The article says the treatment could be approved next year. Details about the drug's name, manufacturer or clinical trial results were not included in the post. The timeline for potential approval remains unconfirmed beyond the article's reporting.